Teva announced the launch of Eptifibatide Injection, the generic version of Merck‘s Integrilin

Integrilin is a GP IIb/IIIa blocker antiplatelet indicated for acute coronary syndrome, including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI), including those undergoing intracoronary stenting.

It works by reversibly inhibiting platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner.

Eptifibatide Injection is available as a 0.75mg/mL, 75mg strength in a 100mL single-use vial. 

For more information call (888) 838-2872 or visit